Mitochondrial OXPHOS Inhibitor

ME-344 is a mitochondrial OXHPHOS inhibitor drug candidate in clinical development to treat solid tumors.

ME-344 is a novel drug candidate that inhibits mitochondrial oxidative phosphorylation (OXPHOS), a fundamental metabolic pathway involved in the production of adenosine triphosphate (ATP) in the mitochondria. Treatment of tumor cells with ME-344 as a single agent results in a rapid loss of ATP and cancer cell death.

Although clinical investigation of ME-344 has demonstrated single agent activity in patients with solid tumors, using it in combination with other cancers therapies is thought to hold more significant potential for patients. Data reported from an investigator-initiated, multi-center, randomized study of ME-344 in combination with the VEGF inhibitor bevacizumab (Avastin®) demonstrated biologic activity in the ME-344 treatment group supporting further clinical investigation.

Additional Information

Mechanism of Action
Development Program
Patient Population:
Clinical Trials

Clinical Trials

MEI is actively recruiting patients to participate in clinical trials to evaluate our investigational cancer therapies.
View All
Patients & Caregivers

Patients & Caregivers

Our driving purpose and principle is simple: deliver novel and differentiated cancer therapies that provide improved outcomes for patients.
Learn More